ACHV

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.

Wall Street analysts forecast ACHV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACHV is 14.60 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Achieve Life Sciences Inc revenue for the last quarter amounts to -14.69M USD, increased 17.86 % YoY.

Achieve Life Sciences Inc. EPS for the last quarter amounts to -11331000.00 USD, increased 9.25 % YoY.

Achieve Life Sciences Inc (ACHV) has 25 emplpoyees as of December 15 2025.

Today ACHV has the market capitalization of 247.01M USD.